Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer’s Dementia in Individuals With Previous Depression
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Depression is associated with an increased risk of Alzheimer's disease. Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram decreases amyloid-β generation and plaque load. The authors evaluated the impact of SSRI treatment on CSF biomarkers and progression from mild cognitive impairment (MCI) to Alzheimer's dementia. METHOD: Data sets from 755 currently nondepressed participants from the longitudinal Alzheimer's Disease Neuroimaging Initiative were evaluated by Kaplan-Meier analysis and analyses of variance and covariance with ApoE4 status and age as covariates. RESULTS: In MCI patients with a history of depression, long-term SSRI treatment (>4 years) was significantly associated with a delayed progression to Alzheimer's dementia by approximately 3 years, compared with short-term SSRI treatment, treatment with other antidepressants, or no treatment and compared with MCI patients without a history of depression. No differences in CSF biomarker levels were observed between treatment groups. CONCLUSIONS: Long-term SSRI treatment may delay progression from MCI to Alzheimer's dementia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The study found that more than 4 years of such treatment was associated with delayed progression to clinically diagnosed Alzheimer's disease.”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [119]
In the citing paper
“and long-term treatment with antidepressants delays the conversion of mild cognitive impairment to Alzheimer’s dementia119.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [119]
In the citing paper
“Recent findings suggest that SSRIs may delay the onset of Alzheimer’s dementia119.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [119]
Citations
Cites
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Diniz, B. S., Butters, M. A., Albert, S. M., Dew, M. A., & Reynolds, C. F. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.118307 · Cited by 1,290
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 1×
“A growing body of evidence points toward a complex role of neuroinflammation in amyloidogenesis, neurodegeneration, and cognitive decline (41).”
Setiawan, E., Wilson, A. A., Mizrahi, R., Rusjan, P. M., Miler, L., Rajkowska, G., Suridjan, I., Kennedy, J. L., Rekkas, P. V., Houle, S., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2427 · Cited by 939 · cited 1×
“Neuroinflammation has also been detected in patients during major depressive episodes (42, 43).”
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572 · cited 1×
“Several randomized and placebocontrolled studies have evaluated the effect of SSRIs on cognition in Alzheimer’s dementia, finding either favorable effects (16, 17), no effects (18–20), or even disadvantageous effects of SSRI treatment (21, 22).”
Modrego, P. J., & Ferrández, J. (2004) · Archives of Neurology · doi:10.1001/archneur.61.8.1290 · Cited by 537 · cited 1×
“This is in contrast to anotherprospectivecohort (30) inwhichahigher rateofMCI progression to Alzheimer’s dementia was found to be associated with depression.”
Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60830-1 · Cited by 532 · cited 1×
“Several randomized and placebocontrolled studies have evaluated the effect of SSRIs on cognition in Alzheimer’s dementia, finding either favorable effects (16, 17), no effects (18–20), or even disadvantageous effects of SSRI treatment (21, 22).”
Depressive symptoms, cognitive decline, and risk of AD in older persons
Wilson, R. S., Barnes, L. L., Mendes de Leon, C. F., Aggarwal, N. T., Schneider, J. S., Bach, J., Pilat, J., Beckett, L. A., Arnold, S. E., Evans, D. A., et al. (2002) · Neurology · doi:10.1212/wnl.59.3.364 · Cited by 528 · cited 1×
“Other studies have found that the severity of depression at baseline was correlated with risk of developing dementia (31).”
Research works printed but not linked: 1
- Bubu OM, Sleep
Cited by
Items 101–200 of 210
Treatment resistant depression in elderly
Wang, S.-C., Yokoyama, J. S., Tzeng, N., Tsai, C.-F., & Liu, M. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2023.02.004 · Cited by 14
Wang, J., Lyu, H., Chen, J., Lin, S., Zheng, H., Li, J., Kong, F., Gao, J., Yu, H., Hu, Y., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200156 · Cited by 12
Different Sides of Depression in the Elderly: An In-depth View on the Role of Aβ Peptides
Pagni, G., Tagliarini, C., Carbone, M. G., Imbimbo, B. P., Marazziti, D., & Pomara, N. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210921164816 · Cited by 12
Sivasaravanaparan, M., Olesen, L. Ø., Severino, M., von Linstow, C. U., Lambertsen, K. L., Gramsbergen, J. B., Hasselstrøm, J. B., Metaxas, A., Wiborg, O., & Finsen, B. R. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220019 · Cited by 11
Shared Mechanisms in Dementia and Depression: The Modulatory Role of Physical Exercise
de Souza, P. B., Rodrigues, A. L. S., & Felice, F. G. D. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70185 · Cited by 15
“Notably, studies have indicated that antidepressant treatment in subjects with dementia may enhance their well-being and/or de-celerate the progression of the disorder (Bartels et al. 2018; Khoury and Grossberg 2019; Zhang, Zheng, and Zhao 2023).”
Nicolai, L., Nettesheim, P., de Witte, L. D., & Snijders, G. J. L. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100465 · Cited by 9
Resolving a paradox: antidepressants, neuroinflammation, and neurodegeneration
Rajkumar, R. P. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00068 · Cited by 9
Mathar, D., Wiebe, A., Tuzsus, D., Knauth, K., & Peters, J. (2023) · Psychophysiology · doi:10.1111/psyp.14381 · Cited by 12
Khan, N. S., Isaza, J. U., Rouhi, N., Jamani, N. F., Jabeen, S., Gill, A. K., Tsutsui, M., Visser, F., & Sargin, D. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00626 · Cited by 11
Anxious–depressive symptoms and sleep disturbances across the Alzheimer disease spectrum
Chai, Y., Kojori, E. S., Saykin, A. J., & Yu, M. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00416-4 · Cited by 8
“Selective serotonin reuptake inhibitors have also been linked to delayed AD progression in MCI patients with a history of depression when used for extended periods 171 .”
Yu, W., Zhang, R., Zhang, A., & Mei, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031234 · Cited by 9
“…(SSRIs) not only prevent the accumulation of A β and Tau [15,16], but also reverse the emotional and cognitive deficits in AD patients and mouse models [17–19], indicating that targeting the serotonergic system could be an effective approach to treat cognitive and psychiatric symptoms of AD.”
Federman, A. D., Becker, J., Carnavali, F., Mindt, M. R., Cho, D., Pandey, G. S., Chan, L., Curtis, L. M., Wolf, M. S., & Wisnivesky, J. P. (2024) · Gerontology and Geriatric Medicine · doi:10.1177/23337214231214217 · Cited by 10
“In MCI, for example, treatment of depression with selective serotonin reuptake inhibitors (SSRI) may reduce depressive symptoms and delay progression to dementia (Bartels et al., 2018; Brendel et al., 2018).”
MethodEpigenetic interventions for brain rejuvenation: anchoring age-related transposons
Sfera, A., Fayard, L., Osorio, C. P., & Price, A. I. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.230283 · Cited by 7
Mental Health of Older Adults: A Global Perspective of Inequalities and Inadequacies
Baiyewu, O., Esan, O., & Elugbadebo, O. O. (2021) · Springer eBooks · doi:10.1007/978-3-319-70134-9_119-1 · Cited by 7
Warren, S. L., Hamza, E. A., Tindle, R., Reid, E., Whitfield, P., Doumit, A., & Moustafa, A. A. (2023) · Current Alzheimer Research · doi:10.2174/0115672050255489231012072014 · Cited by 14
L’utilisation des antidépresseurs dans l’épisode dépressif caractérisé unipolaire du sujet âgé
Péricaud, A., Straczek, C., Montastruc, F., Leboyer, M., Yrondi, A., & Arbus, C. (2022) · L Encéphale · doi:10.1016/j.encep.2021.11.006 · Cited by 11
Chan, C. K., & Rosenberg, P. B. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.8970 · Cited by 6
Fluoxetine Protects Retinal Ischemic Damage in Mice
Romano, G. L., Gozzo, L., Maurel, O. M., Martino, S. D., Riolo, V., Micale, V., Drago, F., & Bucolo, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051370 · Cited by 8
Selective serotonin reuptake inhibitor use, age-related neuropathology and cognition in late-life
Sood, A., Wilson, R. S., Yu, L., Wang, T., Schneider, J. A., Honer, W. G., & Bennett, D. A. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115471 · Cited by 6
Siew, S. K. H., Yu, J., Kua, E. H., & Mahendran, R. (2023) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2023.103503 · Cited by 6
Bogdan, A., Fabre, R., Desmidt, T., Golebiowski, J., Topin, J., Bethus, I., Hanon, O., Boutoleau‐Bretonnière, C., Wagemann, N., Annweiler, C., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230162 · Cited by 6
Yu, C.-C., Wang, X.-F., Wang, J., Li, C., Xiao, J., Wang, X., Han, R., Wang, S., Lin, Y.-F., Kong, L.-H., et al. (2024) · Current Medical Science · doi:10.1007/s11596-024-2908-9 · Cited by 6
Wiltfang, J., Esselmann, H., & Barnikol, U. B. (2021) · Psychiatrische Praxis · doi:10.1055/a-1369-3133 · Cited by 5
“[16] Bartels C, Wagner M, Wolfsgruber S et al.”
BackgroundKim, D.-Y., Kiss, A., Bronskill, S. E., Lanctôt, K. L., Herrmann, N., & Gallagher, D. (2022) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5809 · Cited by 5
“Previous studies have demonstrated a negative association between SSRI use and PET amyloid levels as well as lower risk of AD conversion observed with long‐term SSRI use rather than short‐term use.(30,34) We did not have data regarding duration of use of SSRI/SNRI which was a limitation of this analysis.”
ResultMild Behavioral Impairment: A New Domain of Late-Life Psychiatric Symptoms
Sultzer, D. L. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.03.010 · Cited by 5
Do Antidepressants Increase the Risk of Dementia?
Solomonov, N., & Alexopoulos, G. S. (2019) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.06.004 · Cited by 5
Blaine, B., Kamal, M., Roberts, M., Schickling, B., Lauffer, M., Zhang, Y., Bertolli, A. X., Weber, M. A., Taylor, R., Nadeem, S., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03094-x · Cited by 4
“While parity and SSRI have both previously been associated with reduced neurodegeneration [78, 79], driving mechanisms remain unclear; our results offer a valuable fi rst view.”
A bibliometric analysis of research on dementia comorbid with depression from 2005 to 2024
Li, X., Su, W., & Cai, L. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1508662 · Cited by 6
Kim, J., Ha, T. H., Kim, K., Lee, E.-M., Kim, H., Kim, D. K., Won, H., Lewis, M., Lee, H., & Myung, W. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200994 · Cited by 4
An improved graph Laplacian regularization method for identifying biomarkers of Alzheimer's disease
Liu, L., Liu, X., Zhou, J., Wu, W., & Xiong, L. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111121 · Cited by 4
Lombardi, G., Lombardi, N., Bettiol, A., Crescioli, G., Ferrari, C., Lucidi, G., Polito, C., Berti, V., Bessi, V., Bagnoli, S., et al. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03325-y · Cited by 4
Regen, F., & Benkert, O. (2018) · Springer eBooks · doi:10.1007/978-3-662-57334-1_1 · Cited by 5
Serotonergic Modulators in Alzheimer's Disease: A Hope in the Hopeless Condition
Almohmadi, N. H., Al‐Kuraishy, H. M., Al‐Gareeb, A. I., Albuhadily, A. K., Fakhry, M., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202403401 · Cited by 4
“A cohort study found that SSRIs delay the conversion of mild cognitive impairment to symptomatic AD [87].”
Cumbo, E., & Migliore, D. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251340084 · Cited by 4
Use of Common Psychiatric Medications and Risk and Prognosis of Amyotrophic Lateral Sclerosis
Chourpiliadis, C. P., Lovik, A., Ingre, C., Press, R., Samuelsson, K., Valdimarsdóttir, U. A., & Fang, F. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.14437 · Cited by 3
Depression and Pseudodementia: Decoding the Intricate Bonds in an Italian Outpatient Setting
Buccianelli, B., Marazziti, D., Arone, A., Palermo, S., Simoncini, M., Carbone, M. G., Massoni, L., Violi, M., & Dell’Osso, L. (2023) · Brain Sciences · doi:10.3390/brainsci13081200 · Cited by 7
Bushnell, M. L., Roberts, N. A., & Caraher, K. J. (2024) · Neurologic Clinics · doi:10.1016/j.ncl.2024.05.014 · Cited by 3
Li, Y., Liu, W., Wang, X., Qin, W., Liu, Z., Lyu, D., Li, Y., Li, B., Xu, L., Cao, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70946 · Cited by 3
“8,41,45 Neuroanatomical analyses revealed no differences in cortical thickness or volumetric measurements between treatment groups over the 12-year observation period.”
Lee, Y. J., Kim, H., Jung, J.-H., Han, K., & Jeon, H. J. (2025) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001863 · Cited by 2
Hoertel, N., Mühle, C., MÜLLER, C. P., Chaieb, H., Scheer, V., Fayad, M., Rico, M. S., Limosin, F., & Kornhuber, J. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03649-6 · Cited by 6
“…evidence suggests potential protective effects: long-term SSRI treatment (>4 years) — many SSRIs being FIASMAs — was associated with delayed progression from mild cognitive impairment (MCI) to Alzheimer ’ s dementia by approximately 3 years in patients with depression history (N = 755) [133].”
James, J., Rani, J., & Varadarajan, S. (2022) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2022.v14ti.28 · Cited by 3
Dorey, J., Herrmann, M., Schuster, J.-P., von Gunten, A., & Lepetit, A. (2019) · SERVAL (Université de Lausanne) · doi:10.1016/s0246-1072(19)81456-6 · Cited by 7
Les traitements de la dépression en psychiatrie de liaison : de la théorie à la pratique
Sauvaget, A., Guitteny, M., Bukowski, N., Duffieux, V., Mezouari, A., Brisson, A., Raveneau, C., Gohier, B., & Bulteau, S. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2021.06.012 · Cited by 3
Lange‐Asschenfeldt, C., & Benkert, O. (2020) · Springer eBooks · doi:10.1007/978-3-662-61753-3_6 · Cited by 3
Regen, F., & Benkert, O. (2020) · Springer eBooks · doi:10.1007/978-3-662-61753-3_1 · Cited by 2
Aga, V. M., Shad, M. U., Zhu, H., & Salzman, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-800136-3.00023-5 · Cited by 3
Weight change in people with depression and the risk of dementia: a nationwide cohort study
Kim, H., Jung, J., Han, K., & Jeon, H. J. (2024) · Psychological Medicine · doi:10.1017/s0033291723003124 · Cited by 2
An Overview on Dementia: A Major Symptom of Alzheimer's Disease
Kaur, J., Melkani, I., Singh, A., Singh, A. P., & Bala, K. (2022) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v12i4.5445 · Cited by 2
Regen, F., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_1 · Cited by 1
Choi, J. J., Koscik, R. L., Jonaitis, E. M., Panyard, D. J., Morrow, A. R., Johnson, S. C., Engelman, C. D., & Schmitz, L. (2023) · Metabolites · doi:10.3390/metabo13111154 · Cited by 1
“Depressive symptoms, weekly alcohol consumption, and body mass index (BMI) were measured at each visit and controlled for in the full models because they are potential confounders that are associated with smoking behavior and cognitive outcomes [21–23].”
Comorbidity of Depression and Dementia: Epidemiological, Biological, and Therapeutic Aspects
Петрова, Н. Н. (2025) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-025-01822-y · Cited by 2
“This study found that such treatment for more than four years was associated with a slower progression of clinically diagnosed Alzheimer’s, though whether antidepressant treat-ment reduces the risk of dementia remained open [87, 88].”
Meynadasy, M. A., Sachs‐Ericsson, N., Cushing, S. D., Sheffler, J., Kabbaj, M., & Wilber, A. A. (2025) · The American Journal of Geriatric Psychiatry Open Science Education and Practice · doi:10.1016/j.osep.2025.07.002 · Cited by 1
Eleni, I., Theofanis, V., Zisis, B., & Stamoula, Ε. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.09.010 · Cited by 2
Kandilakis, C. L., Felemegkas, P., Papanastasiou, A. D., Sotiropoulos, I., Kane, J. P. M., Leroi, I., Toledo, J. B., & Alexopoulos, P. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03071-2 · Cited by 1
“Depression, which can precede dementia by several years (Alexopoulos et al. 2025; Bennett and Thomas 2014), engages monoaminergic circuits (Cui et al. 2024) and antidepressant treatment has been associated with slower cognitive decline (Bartels et al. 2018; Kostev et al. 2019).”
Prelog, P. R., Zupan, M., Kramberger, M. G., & Frol, S. (2025) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000549621 · Cited by 1
The Impact of Anticholinergic Burden on the Development of Mild Behavioral Impairment
Franklin, C. A., Rosenberg, P. B., Lyketsos, C. G., Ismail, Z., & Leoutsakos, J. (2026) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2026.05.008 · Cited by 1
Sex differences in psychiatric disorders and their implication for dementia
Biskup, E. M., Jordan, V., Nasta, B., & Rauen, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819344-0.00005-3 · Cited by 2
New Clues to Preclinical Alzheimer’s Disease
Rosenberg, P. B., & Lyketsos, C. G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18010048 · Cited by 1
Can Pharmacological Augmentation of Cognitive Training Remediate Age-Related Cognitive Decline?
Smucny, J., & Carter, C. S. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20040377 · Cited by 1
Neuropsychiatric symptoms in dementia: the psychosocial context
Tan, E. Y. L. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20221104et · Cited by 1
Impact of Musical Therapeutic Intervention on Depression in Dementia Patients and Caregiver BurdenPreprint
Nguyen, H. D., Seki, T., & Chase, W. (2025) · medRxiv · doi:10.1101/2025.07.17.25325681 · Cited by 1
A Geriatrics Perspective on Dementia Prevention and Treatment
Steffens, D. C. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17101155
SSRI verzögern den Übergang in die manifeste Alzheimer-Erkrankung
Broocks, A. (2018) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-018-2626-6
SSRI wirken als Alzheimer-Bremse
Broocks, A. (2018) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-018-0978-y
Promoting Health Behaviors For Aging Persons
Alexopoulos, G. S. (2018) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.12.024
Psychotherapie wird immer wichtiger
Klein, F. (2020) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-020-0588-2
[Drug-support of active therapy for rehabilitation in coronary insufficiency].
Schleusing, G. (1970) · PubMed
19th Latest Advances in Psychiatry International Symposium
(2021) · Progress in Neurology and Psychiatry · doi:10.1002/pnp.710
Cannabidiol and Trazodone Ameliorate Neuronal Proteotoxicity in C. elegansPreprint
Gilberto, V. S., McGrath, S., Alsulami, A., Vidrio-Aguirre, A., & Moreno, J. A. (2022) · Research Square · doi:10.21203/rs.3.rs-2351138/v1
Saida, T., Baba, H., Maeshima, H., Natsume, S., Yoshinari, N., Shimizu, K., & Suzuki, T. (2023) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.6005
Lange‐Asschenfeldt, C., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_6
Carr, D. C., Schmidt, B., Schubert, F. T., & Sachs‐Ericsson, N. (2024) · Aging & Mental Health · doi:10.1080/13607863.2023.2297049
“Moreover, some studies have found that treatment of internalizing disorders, particularly with serotonin re-uptake inhibitors may decrease the negative impact of internalizing symptoms on cognitive decline (Bartels et al., 2018).”
BackgroundThe Impact of Psychopathology and Psychological Well-Being on Cognitive Health
Kua, Z. (2024) · Healthy ageing and longevity · doi:10.1007/978-3-031-68513-2_16
Exploring the Relationship Between Amyloid Burden and Depression in Pre-clinical Alzheimer’s Disease
Benyahia, S. A., Kahlon, S., Rijnhart, J. J. M., & Bishnoi, R. J. (2024) · Cureus · doi:10.7759/cureus.69716
“Alternatively, the treatment of depressive symptoms can also have an impact on the progression of AD by delaying the progression from MCI to the dementia stage [30].”
BackgroundReducing Risk Factors for Mild Cognitive Impairment and Early Dementia
Gerhand, S. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009025911.013
Gründer, G. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21199-7.00002-7
Comorbidity of depression and dementia: epidemiological, biological and therapeutic aspects
Петрова, Н. Н. (2024) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2024124111113
Dhungel, O., Sharma, P., & Sapkota, N. (2025) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175251328472
Current Developments in Alzheimer's Disease and Treatment
Kaya, S., & Yılmaz, İ. (2025) · Anatolian Journal of Pharmaceutical Sciences · doi:10.71133/anatphar.1577117
Treatment of depression comorbid with dementia among the elderly patients
Witkowska, A., Piotrowska, J., Łubińska-Kowalska, A., Domańska, A., Długosz, K. J., Witkowska, A. T., Zapalska, B. A., Żak-Gontarz, A., Minda, A., Janikowska, J., et al. (2025) · Medical Science · doi:10.54905/disssi.v29i158.e73ms3562
Medication Exposure and Neurodegenerative Disease Risk Across National BiobanksPreprint
Levine, K. S., Sargent, L. J., Somerville, E. N., Pitz, V., Price, E. T., Bandrés‐Ciga, S., Simmonds, E., Long, R. A., Jonson, C., Lange, L. M., et al. (2025) · medRxiv · doi:10.1101/2025.07.07.25330740
“19,20 In our study, it was still associated with dementia, even after adjusting for risk conditions and APOE -ε4 status.”
The Neurobiology of Late-Life Depression
Lee, K. J., Kim, H. J., & Kim, Y. (2025) · 신경정신의학 · doi:10.4306/jknpa.2025.64.3.164
Schliep, K. C., Barbeau, W. A., Lynch, K. E., Sorweid, M. K., Varner, M. W., Foster, N. L., & Qeadan, F. (2022) · Figshare · doi:10.6084/m9.figshare.19586923
Schliep, K. C., Barbeau, W. A., Lynch, K. E., Sorweid, M. K., Varner, M. W., Foster, N. L., & Qeadan, F. (2022) · Figshare · doi:10.6084/m9.figshare.19586917
Schliep, K. C., Barbeau, W. A., Lynch, K. E., Sorweid, M. K., Varner, M. W., Foster, N. L., & Qeadan, F. (2022) · Figshare · doi:10.6084/m9.figshare.19586914
Schliep, K. C., Barbeau, W. A., Lynch, K. E., Sorweid, M. K., Varner, M. W., Foster, N. L., & Qeadan, F. (2022) · Figshare · doi:10.6084/m9.figshare.19586929
Schliep, K. C., Barbeau, W. A., Lynch, K. E., Sorweid, M. K., Varner, M. W., Foster, N. L., & Qeadan, F. (2022) · Figshare · doi:10.6084/m9.figshare.19586920
Schliep, K. C., Barbeau, W. A., Lynch, K. E., Sorweid, M. K., Varner, M. W., Foster, N. L., & Qeadan, F. (2022) · Figshare · doi:10.6084/m9.figshare.19586935
He, J.-H., Liu, R.-P., Peng, Y.-M., Guo, Q., 朱兰兵, Lian, Y.-Z., Hu, B.-L., Fan, H.-H., Zhang, X., & Zhu, J.-H. (2021) · Figshare · doi:10.6084/m9.figshare.14060144
He, J.-H., Liu, R.-P., Peng, Y.-M., Guo, Q., 朱兰兵, Lian, Y.-Z., Hu, B.-L., Fan, H.-H., Zhang, X., & Zhu, J.-H. (2021) · Figshare · doi:10.6084/m9.figshare.14059665
BT2 as a novel therapeutic compound for Alzheimer’s disease
Mullins, C. A. (2023) · ThinkTech (Texas Tech University)
Marín Ballarín, R., SERRANO, J. S., & Bueno‐Notivol, J. (2023) · Zaguan (University of Zaragoza Repository)
Modifiable Risk Factors for dementia, awareness of, and barriers to, brain health behaviours
Dukelow, T. (2024) · Trinity's Access to Research Output (TARA) (Trinity College Dublin)
Vire, J. (2024) · UTUPub (University of Turku)
Shaw, J. S., Bray, M. J. C., Harrington, C. K., Rosenberg, P. B., Lyketsos, C. G., & Peters, M. E. (2025) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2025.09.020
Bioinformatics-driven discovery of shared biomarkers linking depression and cognitive impairment
Chen, W., & Li, B. (2026) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/209879
Chang, Y.-J., Huang, S.-C., Chen, Y.-T., & Chuang, H.-C. (2026) · 童綜合醫學雜誌 · doi:10.4103/etmj.etmj-d-25-00023
Marawi, T. (2023) · TSpace (University of Toronto)
Prelog, P. R., Plesnicar, B., Zupan, M., Frol, S., & Kramberger, M. G. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2653170
Management of Concomitant Mental Health Conditions in Older Adults with Cognitive Impairment
Tunink, C., Ulen, M., & McNair, S. H. (2026) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2026.01.010
Metadata
- Authors
- Bartels, C., Wagner, M., Wolfsgruber, S., Ehrenreich, H., Schneider, A., & Initiative, F. T. A. D. N.
- Affiliations
- University of Bonn (DE)
- Venue
- American Journal of Psychiatry
- Published
- 2018-03-01
- Volume
- 175
- Issue
- 3
- Pages
- 232-241
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2768441608
- Semantic Scholar
- 84cf627e767f53e0918c5ac480be02106899308f
- Cited by
- 202
- References
- 50
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 26 · 2023: 26 · 2022: 29 · 2021: 34 · 2020: 15 · 2019: 19 · 2018: 15
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- DZNE Pub (publishedVersion)
- Max Planck Digital Library (submittedVersion)
- GRO (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- selective serotonin reuptake inhibitors, citalopram, mild cognitive impairment, Alzheimer's disease, conversion to dementia, history of depression, cerebrospinal fluid biomarkers, amyloid-beta, APOE ε4, antidepressant treatment duration, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Aged, Alzheimer Disease, Depression, Humans, Risk Factors, Citalopram, Selective Serotonin Reuptake Inhibitors, Kaplan-Meier Estimate, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.